Company intelligence / Profile preview
PURMX Therapeutics
Hiroshima, Hiroshima Prefecture/Hiroshima City, Japanpurmx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company’s lead candidate, MIRX002 (miR‑3140‑3p), an optimized microRNA drug, has entered a first-in-human investigator-led Phase I clinical trial for malignant pleural mesothelioma. Preclinical studies showed potent anti-tumor activity and a wide therapeutic window. The company aims to expand to additional indications such as head and neck cancer and develop new systemic dosage forms.
- Therapeutic areas
- Oncology
- Modalities
- microRNA-based therapeuticsnucleic acid drugs
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Keio Innovation Initiative, Inc.Yokohama Capital
Beyond the preview
Go deeper on PURMX Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PURMX Therapeutics.